Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Neoplasm Metastasis 1Mesothelioma, Malignant 1Lymphoma 1

Interventions

Pemetrexed 13Cisplatin 12Nivolumab 5Carboplatin 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3fludarabine 3defactinib 3amatuximab 2Paclitaxel 2Gemcitabine 2Drug Therapy 2tremelimumab 1tazemetostat 1osimertinib 1napabucasin 1enzalutamide 1bemcentinib 1abemaciclib 1VS-5584 1Trabectedin 1Thiostrepton 1Safety 1Panobinostat 1Monatide (IMS 3015) 1Midazolam 1Letrozole 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma, Malignant × VS-5584 × Clear all
NCT02372227 2017-01-30

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Verastem, Inc.

Phase 1 Terminated
21 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡